UCLA Health Jonsson Comprehensive Cancer Center | Strategic Alliance Partners

Latest from UCLA Health Jonsson Comprehensive Cancer Center

Dr Singer on the Efficacy of IO/TKI Doublets in Advanced RCC

November 09, 2024

Video

Adam E. Singer, MD, PhD, discusses currently available combination treatment regimens for the first-line treatment of patients with renal cell carcinoma.

TROP2 Offers Attractive Therapeutic Target in Breast Cancer and Other Solid Tumors

October 15, 2024

Article

Ian Krop, MD, PhD, and Aditya Bardia, MD, MPH, FASCO, detail how TROP2-directed ADCs have generated excitement in breast cancer and other solid tumors.

Dr McAndrew on a Subgroup Analysis of NATALEE in HR+/HER2– Early Breast Cancer

October 03, 2024

Video

Nicholas P. McAndrew, MD, MSCE, discusses a subgroup analysis of the NATALEE trial in HR+/HER2– early breast cancer by prior systemic treatment.

Breast Cancer Experts Spotlight Early-Phase and Real-World Research at the 2024 ESMO Congress

September 26, 2024

Article

Breast cancer experts highlight early-phase and real-world studies of interest from the 2024 ESMO Congress.

Dr Drakaki on a Case Study in ALK+ Refractory Metastatic RCC

September 24, 2024

Video

Alexandra Drakaki, MD, PhD, discusses a case study of a patient with refractory metastatic renal cell carcinoma harboring an ALK rearrangement.

Dr Singer on the Lack of Clinical Benefit for Immunotherapy Rechallenge in Advanced RCC

September 23, 2024

Video

Adam Singer, MD, PhD, discusses the lack of clinical benefit for sequential immunotherapy in advanced renal cell carcinoma.

Dr Drakaki on Paradigm-Shifting Trials in Non–Clear Cell RCC

September 19, 2024

Video

Alexandra Drakaki, MD, PhD, discusses key trials that have shaped the treatment paradigm in non–clear cell renal cell carcinoma.

Dr Drakaki on the Evolution of Non–Clear Cell RCC Subtype Classifications

September 18, 2024

Video

Alexandra Drakaki, MD, PhD, discusses how the classification of subtypes of non–clear cell renal cell carcinoma has evolved in recent years.

Cabozantinib/Nivolumab Combination Findings Further Inform RCC Care

September 13, 2024

Article

Adam E. Singer, MD, PhD, highlights how cabozantinib and nivolumab treatment compares with other therapies in terms of efficacy and safety in RCC.

More Precise Classifications of Non–Clear Cell RCC Are Required to Improve Personalized Treatment

September 12, 2024

Article

Alexandra Drakaki, MD, expands on the need to improve specific classifications in non–clear cell renal cell carcinoma.

Histologic Features, Risk Help Reduce Uncertainties Around Frontline Treatment Selection in RCC

September 12, 2024

Article

Adam E. Singer, MD, PhD, details how he selects between the available TKI/IO combinations and the only dual immunotherapy regimen for patients with RCC.

Dr Drakaki on the Investigation of Zanzalintinib in Advanced Non–Clear Cell RCC

September 10, 2024

Video

Alexandra Drakaki, MD, PhD, discusses the potential role of zanzalintinib in advanced non–clear cell renal cell carcinoma.

Dr Yuan on Minimizing Lymph Node Surgical Intervention in Breast Cancer

September 10, 2024

Video

Yuan Yuan, MD, PhD, discusses the potential shift towards minimizing surgical intervention for lymph node management in breast cancer.

Dr Chase on the FDA Approval of Dostarlimab Plus Chemotherapy in Endometrial Cancer

August 30, 2024

Video

Dana M. Chase, MD, discusses the FDA approval of dostarlimab plus chemotherapy for patients with primary advanced or recurrent endometrial cancer.

Key Takeaways and Closing Thoughts on ADCs

August 29, 2024

Video

Experts discuss key takeaways and closing thoughts on antibody-drug conjugates (ADCs) in cancer treatment.

The Future for HER2-Directed ADCs

August 29, 2024

Video

Ronan Kelly, MD, MBA, offers insights on the future for HER2-directed antibody-drug conjugates.

Insights on T-DXd Approval as Tumor-Agnostic HER2-Directed Therapy

August 29, 2024

Video

Ronan Kelly, MD, MBA, offers insights on trastuzumab deruxtecan approval as tumor-agnostic HER2-directed therapy.

Novel Targets Facilitate Treatment Advances and Spur Further Questions in Endometrial Cancer

August 28, 2024

Article

Ritu Salani, MD, discusses the development of ADCs, the potential role of selinexor, and the use of PARP inhibitors across endometrial cancer subsets.

PARP Inhibitors and ADCs Spark Change Across Ovarian and Cervical Cancer Paradigms

August 26, 2024

Article

Ritu Salani, MD, discusses the role of ADCs in ovarian cancer and what the future of the post-IO setting in cervical cancer management may look like.

Emerging ADCs in Development

August 22, 2024

Video

Key opinion leaders examine promising antibody-drug conjugates (ADCs) in the pharmaceutical development pipeline.